Home/Pipeline/MOT™ for ALS

MOT™ for ALS

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical

Status

Active

Company

MitoSense

About MitoSense

MitoSense is a private, preclinical-stage biotech founded in 2017, pioneering a first-in-class cellular biotherapy based on transplanting functional mitochondria. Its lead focus is on Amyotrophic Lateral Sclerosis (ALS), with potential applications across a broad spectrum of neurodegenerative disorders. The company leverages an experienced leadership team and is built upon foundational research by Dr. Robert Elliott, positioning it to address major unmet medical needs in a large and growing market.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active